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Purpose: Placebo analgesia refers to a perceived reduction in pain intensity following the 
administration of a simulated or otherwise medically ineffective treatment. Previous studies 
have shown that many factors can influence the magnitude of placebo analgesia. However, few 
investigations have examined the effect of age on placebo analgesia, and none have done it in 
the context of electrotherapeutic interventions. The objective of this study is to compare the 
placebo response induced by sham transcutaneous electrical nerve stimulation (TENS) between 
young and older individuals, using an experimental heat-pain paradigm.
Patients and methods: Twenty-two young (21–39 years) and 22 older (58–76 years) healthy 
adults participated in this comparative study. Experimental heat pain was evoked with a thermode 
(2-min stimulation at a constant individually adjusted temperature) applied on the lumbar region. 
Participants were asked to evaluate the intensity of their pain using a computerized visual analog 
scale. Experimental pain was induced before and after an unconditioned placebo intervention 
(placebo TENS) applied for 25 min.
Results: In young individuals, no significant pain reductions were noted, whereas in older 
individuals, a statistically significant pain reduction was observed after the placebo stimulation 
(P,0.01). Between-group analyses revealed that placebo analgesia was greater in older indi-
viduals (40% pain reduction) compared with young individuals (15% pain reduction) (P,0.05). 
However, sham TENS increased heat-pain thresholds in the young group (P,0.01), but not in 
the older group (P=0.43).
Conclusion: Our results indicate that placebo analgesia is influenced by age, with older 
individuals showing larger placebo analgesia than young adults. Although these results should 
be confirmed in clinical pain populations, the current observations bear potentially important 
consequences for the design of future placebo-controlled trials and for healthcare professionals 
working with elderly patients.
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Plain language summary
Simulated medical interventions (commonly referred to as placebo treatments) have been shown 
to reduce pain in many individuals. The magnitude of pain reduction following the administration 
of a placebo treatment is affected by many factors. The objective of this study was to determine 
whether age influences the magnitude of placebo analgesia. To do this, we compared the effect of 
a simulated treatment commonly used in rehabilitation (transcutaneous electrical nerve stimula-
tion or TENS) on pain between young and elderly individuals. We observed that the magnitude 
of the placebo response was greater in older individuals, compared to young individuals, sug-
gesting that age is a key factor that can affect the magnitude of the placebo effect.
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Introduction
Placebo analgesia refers to a perceived reduction in pain 
following the administration of a simulated or otherwise 
medically inactive treatment.1 Placebo analgesia has been 
observed in healthy individuals and chronic pain patients.2,3 
Placebo effects can have diverse consequences on health 
problems in medical practice and clinical research.4 The 
magnitude of placebo analgesia is known to be influenced 
by numerous factors, including conditioning,5,6 emotions,7 
motivation,8 verbal suggestions,9 social observation,10 prior 
experience,2,11 and previous treatments.3
The mechanisms involved in placebo analgesia are still 
incompletely understood, but are believed to rely on the 
activation of endogenous pain-modulation systems.12,13 Past 
observations have suggested that the efficacy of these endoge-
nous pain-modulation systems decreases with age,14–16 raising 
the possibility that older individuals could show reduced 
placebo responses, compared with young individuals.17
To date, few investigators have studied the effect of age 
on placebo analgesia and those who did have reported con-
troversial results.18–20 For instance, Lasagna et al observed 
in a group of postoperative patients that placebo responders 
were, on average, older than placebo non-responders.18 This 
observation suggests that the analgesic effect of a placebo 
intervention (in this case, the administration of a simulated 
analgesic solution via perfusion) is greater in elderly indi-
viduals. This interpretation was challenged by the results 
of Ho et al, who observed that the pain-inhibitory effect of 
a placebo pill was higher in young patients compared with 
older patients in a population of individuals suffering from 
migraine.19 These inconsistencies could be due to different 
routes of administration (injection versus pill) or the pain 
population studied (type of pain).21 To our knowledge, no 
studies have investigated the effect of age on the placebo 
effect triggered by electrotherapeutic interventions.
The aim of the present study was to compare the magni-
tude of placebo analgesia between a group of young and a 
group of older individuals using an experimental heat-pain 
paradigm and an unconditioned placebo electrotherapeutic 
intervention (sham transcutaneous electrical nerve stimu-
lation [TENS]). We hypothesized that young individuals 
would show higher placebo analgesic responses than older 
individuals after the placebo TENS intervention.
Patients and methods
Participants
Twenty-two young (21–39 years) and 22 older (58–76 years) 
healthy adults were included in the study. For safety reasons, 
individuals with pacemakers or metal implants were 
excluded, as were pregnant women. People suffering from an 
existing neurological or pain condition were also excluded. 
Individuals with prior experience with TENS treatments were 
not included in this investigation. Participants were asked 
to refrain from consuming caffeine and tobacco products 
3 hours before and short-term analgesics (for acute pain 
such as headache, fever, etc.) 6 hours before testing. The 
experiment took place at the Research Center on Aging 
of the Centre intégré universitaire de santé et de services 
sociaux (CIUSSS) de l’Estrie-CHUS between November 
2012 and May 2016. Participants were all French-speaking 
community-dwelling individuals. The study was approved 
by the CIUSSS de l’Estrie Research Ethics Committee 
(Approval # 21-01-2016), and each participant provided 
written informed consent before participating in the study.
Pain evaluations
Participants assessed their pain perception using a com-
puterized visual analog scale (CoVAS; Medoc Advanced 
Medical Systems, Ramat Yishai, Israel) ranging from 0 (no 
pain) to 100 (intolerable pain) during tonic heat-pain tests 
performed before and after the placebo intervention. This 
method of pain evaluation has been validated and has a 
good reliability.22–24
Tonic heat-pain test
At the beginning of the experimental session, a pretest 
was conducted to familiarize participants with the CoVAS 
and the Peltier-type thermode (30×30 mm, TSA-II, Medoc 
advanced Medical Systems) used to induce experimental 
pain. During the pretest, the thermode was placed on the 
lower thoracic region of the back of the participants. Ther-
mode temperature gradually rose from 32°C to 51°C (rising 
rate =0.3°C/sec). Participants used the CoVAS to assess their 
pain during the thermode stimulation. They were instructed 
to start moving the cursor of the CoVAS when they started 
to feel pain (pain perception threshold) and that the cur-
sor needed to be at “100” mark when pain was unbearable 
(100/100; pain tolerance threshold). This procedure was 
repeated until the pain reports were consistent between tri-
als (#1°C difference for pain perception and pain tolerance 
thresholds).
The tonic heat pain test (thermal temporal summation 
paradigm) consisted in the application of the thermode on 
the lumbar region at a constant temperature (individually 
adapted) for 2 min.25 Participants were told that the thermode 
temperature could rise, remain stable, or decrease during 
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the test. In fact, after a constant rise (1°C/sec) from baseline 
(32°C) to the individually predetermined temperature, the 
temperature of the thermode remained constant throughout 
the whole 2-min heat-pain test. Mentioning that the tempera-
ture could rise, remain stable, or decrease during the heat 
pain test ensured that participants provide a timely accurate 
evaluation of their pain, without creating expectations with 
regard to the nociceptive stimulus, and influencing pain 
assessment (see Tousignant-Laflamme et al25 for a similar 
approach). The short-term (within-day) and long-term 
(between days) test–retest reliability of individualized ther-
mal temporal summation paradigms is well established.26
The temperature used during the heat-pain test was 
determined during the pretest (temperature rated at 50/100 
with the CoVAS).25,27 Participants assessed their pain with 
the CoVAS during the 2-min test. Mean pain intensity ratings 
obtained during the 2-min heat-pain test were calculated and 
used in subsequent analyses. The heat-pain test was per-
formed on 5 occasions, always using the same individually 
adapted thermode temperature: 1) at baseline (T0), 2) during 
the placebo intervention (T1; after 15 min of sham TENS), 
3) immediately after the placebo intervention (T2; at the end 
of the 25 min of sham TENS), 4) 15 min after the placebo 
TENS intervention (T3), and 5) 30 min after the placebo 
TENS intervention (T4). To avoid pain sensitization, the 
thermode was applied on adjacent regions of the lumbar 
region, and never on the exact same site.
heat-pain threshold
Heat-pain thresholds (HPTs) were evaluated on the lumbar 
region with the thermode, using the method of limits.22,28 
Participants were advised that the temperature of the ther-
mode would gradually increase and that they would need to 
report their first pain sensation by clicking the left button of 
a computer mouse (baseline =32°C; rising rate =0.3°C/sec). 
HPTs were measured at baseline (T0), during the placebo 
intervention (T1; after 15 min of sham TENS), and immedi-
ately after the placebo intervention (T2). A total of 3 HPTs 
values were taken at each time measure and then averaged 
to obtain a single HPT value.
Placebo intervention
The placebo intervention was a sham TENS intervention 
that was delivered using 2 pairs of rubber silicone electrodes 
connected to a digital Eclipse Plus apparatus (Empi, St Paul, 
MN, USA), applied for 25 min. Electrodes were placed on the 
lower thoracic and lumbar regions. The frequency was set at 
100 Hz and the pulse duration at 60 µs. However, the TENS 
apparatus was inactivated using a hidden device, which 
disabled the electrodes (electric stimulation was applied to 
built-in resistors) without changing the TENS equipment 
display. The participants were told that there was an electric 
current (indication of stimulation on the TENS device). 
In reality, the electric current was dissipated in the resistors, 
and no electrical stimulation was given to the participants.
Expectations of pain modification
The participants communicated their expectations 2 min 
before the application of sham TENS (before the first heat-
pain test [T0]) and 2 min after the start of the sham TENS 
stimulation (before the second heat-pain test [T1]). Before the 
stimulation, these expectations were reported to the experi-
menter, whereas during the placebo TENS intervention, 
the therapist assessed the expectations of the participants. 
Volunteers were asked to evaluate the effect they expected the 
TENS intervention would have on pain intensity (increase, no 
change, or decrease). The consent form specified that TENS 
is an electrotherapeutic modality commonly used to stimulate 
peripheral nerves and reduce pain. Participants were also 
informed that the aim of the study was to evaluate the effect 
of a specific type of TENS treatment on pain. Participants did 
not receive any further guidance with regard to the expected 
effect of TENS intervention. Subsequently, participants had 
to estimate a percentage of expected pain variation (0%= no 
change; +100%= total pain decrease; -100%= strong pain 
increase). Expectations were gathered for 30 of the 44 par-
ticipants (14 young and 16 older adults).
sample size and statistical analysis
To facilitate comparisons, and because pain ratings were 
obtained continuously during the 2-min tonic heat-pain test 
(CoVAS sampling rate =10 Hz), the pain intensity ratings 
obtained during each 2-min tonic heat-pain test were aver-
aged for each participant and time point, and the mean was 
used in subsequent analyses. The amplitude of the placebo 
effect (% of change in pain) was calculated using the follow-
ing formula: ([T0 pain intensity - T2 pain intensity]/T0 pain 
intensity) ×100. The study was designed to detect a between-
group difference of 20 points on the CoVAS (clinically 
important difference).29 To detect this difference, with 80% 
statistical power and a 5% significance level, we determined 
that 22 young and 22 older adults should be enrolled in the 
study (estimated SD of 23, based on preliminary results).
Given the small number of participants and because visual 
inspection of the histograms (frequency distribution) did not 
allow us to assume that the data were normally distributed, 
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nonparametric tests were used. Friedman tests and Wilcoxon 
signed-rank tests were used to compare the pain intensity scores 
and the HPTs before, during, and after the placebo intervention 
(within-subject analysis). This allowed us to determine whether 
the sham TENS treatment influenced pain perception. Mann–
Whitney tests were used to compare the pain intensity scores, 
HPT, and the magnitude of placebo analgesia (% change in 
pain) between the young and the older groups (between subject 
analyses). Statistical differences were considered significant if 
P,0.05 was obtained. All tests were performed using SPSS 
(version 19.0 for Windows, Chicago, IL, USA).
Results
Characteristics of the participants
Of the 50 participants who reported interest to take part in the 
study, 49 met the inclusion criteria (Figure 1). Five partici-
pants withdrew before the intervention started for personal 
reasons. Twenty-two young participants aged 21–39 years 
(mean: 27; 11 men and 11 women) and 22 older individuals 
aged 58–76 years (mean: 67; 11 men and 11 women) completed 
the study. Stimulation temperatures for the heat-pain tests at 
baseline were comparable between young (45.9°C±0.5°C) 
and older participants (46.5°C±0.4°C; P=0.53).
Pain intensity during heat-pain tests
The average pain intensity scores obtained for the heat-pain 
tests before, during, and after the placebo intervention are 
presented in Figure 2. Every participant experienced pain 
before placebo TENS application (T0; all pain intensity 
scores .17). Mann–Whitney tests showed that mean pain 
intensity ratings obtained during the tonic heat-pain test at 
baseline (T0) did not differ between the young (42.4±2.7) 
and the older groups (41.0±3.2; P=0.97).
Pain intensity tended to decrease after the sham TENS 
stimulation in young and older adults. However, no sig-
nificant pain reduction was observed at T1, T2, T3, and T4 
in the young group, when compared with baseline (T0; all 
Ps.0.05). As depicted in Figure 2, the pain reductions 
were of greater magnitude in the older group. This was con-
firmed by the Friedman test, which revealed a statistically 
significant difference in pain in the older group (P,0.01). 
Wilcoxon signed-rank tests further revealed statistically 
significant reductions in pain scores in the older group 
after the sham TENS application (T2, T3, and T4) when 
compared with baseline (T0; all Ps,0.01). Pain reduction 
during sham TENS application (T1) did not reach statistical 
significance (P=0.07).
Mann–Whitney tests were also used to directly compare 
the pain scores during and after TENS application between 
the young and the old groups. Results showed that the pain 
intensity ratings were significantly lower in the older group 
immediately after (T2) and 15 min after (T3) TENS stimu-
lation, compared with the young group (all Ps#0.01), once 
again suggesting a greater placebo effect in the older group. 
Pain evaluations were comparable between the groups during 
TENS (T1), as well as 30 min after the end of the placebo 
intervention (T4; all Ps.0.05).
Magnitude of placebo analgesia
The magnitude of placebo analgesia (% change in pain) in the 
young and the older groups is shown in Figure 3. As it can 
be seen from the figure, the amplitude of the placebo effect 
was larger in the older group than in the young group, both 
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Figure 1 Flow chart for study participant enrollment.
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Figure 2 Mean (±seM) pain intensity before (T0), during (T1), immediately after (T2), 
15 min after (T3), and 30 min after (T4) sham Tens.
Notes: *P,0.05 for pain intensity in the older group during (T1) and after the 
sham Tens application (T2, T3 and T4) compared to baseline (T0). ^P,0.05 for the 
difference in pain scores at T2 and T3 between the young and the older groups.
Abbreviations: CoVAs, computerized visual analog scale; seM, standard error of 
the mean; Tens, transcutaneous electrical nerve stimulation.
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immediately after (T2; P,0.05) and 15 min after (T3; P,0.05) 
the sham TENS intervention. Differences in placebo effects 
during (T1; P=0.15) and 30 min after (T4; P=0.09) sham 
TENS stimulation failed to reach statistical significance.
heat-pain threshold
HPTs obtained before, during, and after the placebo interven-
tion are presented in Table 1. Baseline HPTs were compa-
rable between groups (P=0.92). Friedman tests revealed that 
sham TENS increased HPT in the young group (P,0.01), 
but not in the older group (P=0.43). In the young group, the 
HPTs increase reached statistical significance during (T1) 
and after (T2) the placebo intervention when compared with 
baseline (all P,0.05).
Expectations of pain modification
Seven (5 in the young and 2 in the older groups) of the 
44 participants identified the presence of a placebo treatment 
(success rate of blinding 84%). Before the placebo TENS 
stimulation, young adults expected an average pain reduction 
of 33%±19%, whereas older individuals expected a pain 
reduction of 9%±27% (P,0.05; see Figure 4). However, 
during the placebo TENS intervention, expectations were 
around 25% of pain reduction in both groups (P=0.75). 
Hence, in the older group, expectations were higher during 
the treatment than before the intervention (P,0.05), whereas 
expectations did not change significantly in the young 
group (P=0.17).
Discussion
The objective of this study was to better understand the 
effects of age on the placebo analgesia induced by an elec-
trotherapeutic intervention. Contrary to our initial hypothesis, 
we observed that the placebo response was stronger in older 
than in young individuals. This difference was considerable, 
with pain reductions being more than twice as important 
in the older group. These observations are in line with the 
results of Lasagna et al who reported in a group of post-
operative patients, that placebo responders tended to be 
older than placebo non-responders.18 However, these results 
are in opposition with the results of Ho et al19 and Wrobel 
et al.20 These discrepancies could be due to the characteristics 
of the placebo treatment administered (pharmacological versus 
non-pharmacological interventions), the population studied 
(acute, chronic/recurrent pain, or experimental pain), and the 
paradigm used (presence/absence of a conditioning phase).8
effect of placebo Tens on hPTs
Our results show a significant, although relatively small 
(,1.0°C), increase in HPTs after placebo TENS stimulation 
in the young group, suggesting a hypoalgesic placebo effect. 
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Figure 3 Mean (±seM) placebo analgesia (% change in pain intensity) in the young 
group (n=22) and the older group (n=22) during (T1), immediately after (T2), 15 min 
after (T3), and 30 min after (T4) sham Tens. *P,0.05 the difference between young 
and older groups.
Abbreviations: seM, standard error of the mean; Tens, transcutaneous electrical 
nerve stimulation.
Table 1 Mean (±seM) heat-pain thresholds before, during, and 
after sham Tens stimulation
Heat-pain 
thresholds (°C)
Young 
(n=22)
Older 
(n=22)
T0 – before 42.7 (±0.6) 42.7 (±0.6)
T1 – during 43.2 (±0.6)* 43.1 (±0.6)
T2 – after 43.5 (±0.6)* 42.4 (±1.0)
Note: *P,0.05 for the difference between before, during, and after placebo Tens 
stimulation.
Abbreviations: seM, standard error of the mean; Tens, transcutaneous electrical 
nerve stimulation.
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Figure 4 Mean (±seM) expectations for pain variations before and during sham 
Tens stimulation in the young (n=14) and the older group (n=16). *P,0.05 the 
difference between young and older groups.
Abbreviations: seM, standard error of the mean; Tens, transcutaneous electrical 
nerve stimulation.
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Previous studies have shown comparable pain thresholds 
increments after the administration of placebo treatments in 
young individuals.30,31 Increments in HPT of ~1.0°C were 
observed after intravenous administration of low doses of a 
potent opioid analgesic drug (remifentanil 0.05 µg/kg/min),32 
suggesting that even small increases in HPT can be clini-
cally significant. However, in the absence of specific values 
defining a clinically significant change for HPT, it is difficult 
to determine if the changes noted in this study are of clinical 
importance. Surprisingly, in the older group, HPTs did not 
change after the placebo TENS stimulation. This absence 
of significant change could partly be explained by the high 
variability of HPT responses after the placebo intervention 
in the older group. This high variability has been reported in 
elderly individuals for other types of measures.33
Psychological and neurophysiological 
factors
Age differences in placebo analgesia effectiveness could be 
attributable to psychological factors.34 Numerous studies have 
shown that psychological factors, such as conditioning,5,6 
emotions,7 motivation,8 and previous experience,10,11 can 
influence the magnitude of placebo analgesia. Some evidence 
suggests that expectation and conditioning are 2 of the most 
influential factors, with high expectations or a high condition-
ing effect being associated with greater placebo effects. Some 
researchers have suggested that conditioning and expecta-
tions are intrinsically interconnected.35 Conditioning is, in 
fact, often seen as a potent and effective way to increase the 
expectations related to a given intervention.5,6 Investigators 
supporting this interpretation showed that previous experi-
ence influences both expectations and the magnitude of 
placebo analgesia.2,35 In that sense, the larger placebo effect 
noted in elderly individuals could potentially be explained by 
the fact that older individuals have received a greater number 
of effective treatments during their lifetime, which acted as 
positive conditioning procedures.
If this holds true, older individuals would be expected 
to have higher expectations. On the contrary, we observed 
that older individuals had lower expectations with regard to 
sham TENS before application. Surprisingly, the expecta-
tions of older individuals significantly increased once the 
sham intervention was initiated. It remains uncertain why the 
expectations of the participants of the older group changed 
over time. Perhaps older individuals became more confident 
with regard to the intervention when they were taken in 
charge by the therapist and saw the TENS apparatus. Future 
studies are required to test this hypothesis and determine 
if factors related to the therapist and/or the intervention 
can differentially influence the expectations of young and 
older individuals.
Age differences in the magnitude of placebo analgesia 
could also be explained by neurophysiological factors. 
Indeed, placebo analgesia has been thought to rely on the 
activation of descending pain-modulating mechanisms12,13 
and these endogenous pain-modulation systems have been 
shown to be less efficient in elderly individuals.14–16 In this 
case, the presence of a defective top–down circuitry suggests 
that other mechanisms (eg, top–top modulation) could step in. 
For instance, a functional compensatory mechanism, named 
the posterior-anterior shift in aging, has been observed in 
older adults.36–39 These studies, which compared brain activity 
measures between young and older adults, have reported 
increased activity in the prefrontal cortex and decreased 
activity in the occipital cortex in older individuals during 
working memory and visual attention tasks.36,37 Similar 
cerebral mechanisms could be triggered in the context of 
a therapeutic treatment and may potentially explain why 
elderly individuals show preserved/increased placebo 
response, despite defective top–down circuitry.
limitations
The tonic heat-pain paradigm that was used in this study is a 
well-validated model, but does not reflect clinical pain situa-
tions. Indeed, the mechanisms involved in placebo analgesia 
may vary between healthy individuals and patients suffering 
from chronic pain. Reproducing these results in clinical 
pain populations is warranted before any final conclusion 
can be made.
When participants were asked at the end of the testing 
session if they thought that the TENS stimulation was 
effective, 7 of them (16%) identified the presence of a sham 
condition. However, most participants (84%) did not comment 
on sham or placebo, suggesting that blinding was generally 
preserved. Moreover, it should be noted that expectations with 
regard to the effectiveness of sham TENS were not gathered 
for the first 14 of the 44 participants. Nevertheless, expecta-
tions were evaluated in a similar number of young (n=14) and 
older (n=16) adults, and it is unlikely that the missing values 
would have affected the interpretation of our results.
Finally, it should be noted that previous pain experiences 
(including prior analgesic efficacy, medical conditions, 
stressful life events, coping strategies, and other psychological 
characteristics such as anxiety and depression) that could 
potentially affect placebo analgesia were not evaluated in 
the current study.
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Conclusion
The main point that emerges from this study is that the 
magnitude of placebo analgesia triggered by a common 
electrotherapeutic intervention (TENS) is greater in older 
than in young adults. This difference could be related to 
a difference in psychological factors, neurophysiological 
mechanisms, or a combination of both. Although these results 
still need to be confirmed in clinical pain populations, the 
current observations suggest that age is a factor that should 
be considered in clinical practice, as well as in upcoming 
clinical trials. Further studies are necessary to identify the 
psychobiological mechanisms underlying the age-related 
differences in placebo analgesia.
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